Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Campisi (Catania, Italy), C. Crimi (Catania, Italy), A. Noto (Messina, Italy), M. Foschino (Foggia, Italy), G. Valenti (Palermo, Italy), V. Viviano (Palermo, Italy), C. Pelaia (Catanzaro, Italy), L. Ricciardi (Messina, Italy), N. Scichilone (Palermo, Italy), N. Crimi (Catania, Italy). Adherence to omalizumab: a “real-life” study. 2525

Member's Comments

No comment yet.

Related content which might interest you: Asthma control with inhaled corticosteroid therapy: A real-world observational study Source: Annual Congress 2010 - Management of airway disease Year: 2010 Italian real-life experience of omalizumab Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Clinical and economic outcomes following 52-week add-on omalizumab Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial Source: Eur Respir J, 55 (4) 1902073; 10.1183/13993003.02073-2019 Year: 2020 Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL study Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Efficacy and safety of omalizumab in real-life practice in India Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT) Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018